AI3 Bio, Inc.

BiotechnologyBiotechnologyAutoimmuneSeries A

📍 Watertown, MA, United States

StreetZero Signal 82

Be the first to signal interest

About AI3 Bio, Inc.

ai3Bio is a biotechnology company targeting autoimmune disease at its root source. The company's proprietary antibody and lipid nanoparticle-based technologies reset the immune system by directly targeting and eliminating disease-causing Th17 cells in vivo, in a single step. ai3Bio launched on September 29, 2026, with $48 million in Series A funding to advance both of its platforms, including IND-enabling studies.

LATEST FUNDINGSeries A

$48.3M

Announced 2026-11-04

TOTAL RAISED$48M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for AI3 Bio, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED—

HQWatertown, MA, United States

Industry

Biotechnology

Investors

UPMC Enterprises Ziff Capital Partners Cockrell Interests Tanis Ventures

Key highlights

Launched September 2026 with $48M Series A to advance Th17-targeting platforms.
Led by UPMC Enterprises and Ziff Capital Partners with Cockrell and Tanis participation.
Focuses on in vivo elimination of disease-causing Th17 cells via antibody and LNP technologies.
John Maraganore of Alnylam serves as strategic advisor.
Total funding to date stands at $48 million per multiple announcements.

Ask StreetZero about AI3 Bio, Inc.

Put our AI to work on this deal.

What is AI3 Bio, Inc.'s value proposition?Who are AI3 Bio, Inc.'s competitors?Why does this raise matter?Summarize AI3 Bio, Inc. for an investor.

Similar companies

Other Biotechnology deals, ranked by Signal.

Elucid Bioimaging Inc.

$56.2M

BigHat Biosciences, Inc.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.